Log In
BCIQ
Print this Print this
 

PT20

  Manage Alerts
Collapse Summary General Information
Company Phosphate Therapeutics Ltd.
DescriptionIron-based phosphate binder
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationHyperphosphatemia
Indication DetailsTreat hyperphosphatemia; Treat hyperphosphatemia in patients with pre-dialysis and dialysis-dependent chronic kidney disease (CKD)
Regulatory Designation
PartnerShield Therapeutics plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today